Co-Authors
This is a "connection" page, showing publications co-authored by JACK A ROTH and MIN JIN HA.
Connection Strength
1.200
-
Author Correction: 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib. Commun Biol. 2023 Jun 06; 6(1):608.
Score: 0.226
-
3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib. Commun Biol. 2023 05 11; 6(1):509.
Score: 0.225
-
CombPDX: a unified statistical framework for evaluating drug synergism in patient-derived xenografts. Sci Rep. 2022 07 29; 12(1):12984.
Score: 0.213
-
TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model. Commun Biol. 2022 02 24; 5(1):167.
Score: 0.207
-
An Improved Patient-Derived Xenograft Humanized Mouse Model for Evaluation of Lung Cancer Immune Responses. Cancer Immunol Res. 2019 08; 7(8):1267-1279.
Score: 0.171
-
Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations. Mol Cancer Ther. 2024 Jul 02; 23(7):924-938.
Score: 0.061
-
Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations. Sci Rep. 2022 01 24; 12(1):1248.
Score: 0.051
-
KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations. Am J Cancer Res. 2020; 10(12):4464-4475.
Score: 0.047